Company facts
- Industry
- Pharmaceutical Preparations
- Headquarters
- Paramus, New Jersey
- Most recent report
- 8-K, filed Sep 1, 2026
- Incorporated
- Wyoming
- Filings on record
- 34 filings
- On EDGAR
- CIK 2075320
- Fiscal year ends
- December
- Filer status
- Emerging growth company
Financials 3
News 4
Prospectuses and Registrations 5
Proxies 2
Ownership 8 of 10
- 4 Insider reported a trade May 28, 2026
- 4 Insider reported a trade Feb 20, 2026
- SCHEDULE 13D Large holder reported an active stake Feb 5, 2026
- 3 Insider reported their initial holding Jan 29, 2026
- 3 Insider reported their initial holding Jan 29, 2026
- 3 Insider reported their initial holding Jan 29, 2026
- 3 Insider reported their initial holding Jan 29, 2026
- 3 Insider reported their initial holding Jan 29, 2026
Other 8 of 10
- ARS Annual report sent to shareholders Jul 28, 2026
- EFFECT Notice that a registration became effective Jan 29, 2026
- CERT Exchange certified a listing Jan 28, 2026
- 8-A12B Registration of a security for exchange listing Jan 27, 2026
- C-U Oct 31, 2025
- C-U Oct 27, 2025
- C/A Amended filing Oct 1, 2025
- DRS/A Draft registration statement, submitted confidentially, amended Sep 19, 2025
Everything here comes from Polaryx Therapeutics, Inc.'s own filings on SEC EDGAR. The filing list is rechecked every hour.